ERT Launches Centralized Cardiac Safety 2.0: A New Approach to ECG Management in Clinical Trials
ERT, a provider of centralized services to the biopharmaceutical, medical device and related industries, announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a new approach to cardiac safety in clinical trials. These new solutions were developed to overcome many of the perceived barriers to centralizing all ECGs in clinical trials. ERT’s aim is to improve the science of cardiac safety while helping sponsors reduce overall costs with the adoption of a fully centralized approach.
ERT’s Centralized Cardiac Safety 2.0 strives to improve data quality, reduce the investigator workload and improve the overall user experience at the investigative site. The commercial value to sponsors and contract research organizations is derived from cost savings and more efficient operations across entire programs of drug development.
As part of the Centralized Cardiac Safety 2.0 solution, ERT has also introduced ELI-PC from Mortara Instrument. TThis small hand-held ECG collection device aims to make it easier for companies to adopt a centralized system as it interacts automatically with the central database.
Integration of this new ECG machine into computer systems will enable key information, such as patient demographics, to be automatically downloaded before a trial.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
